INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Corporate insider
GK

Goodrich Katherine

DirectorCIK 0002044770

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 1
Max Insider Score31
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A—
3,837 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Tarsus Pharmaceuticals, Inc.Director · Jan 14, 2026
5
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Grant or award
A
—
2,417 sh
Jun 25, 2026
Jun 29, 2026
traded Jun 25, 2026
+4d
SEC FORM 4

Evidence

25
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$183K
2,954 sh
Jun 15, 2026Jun 17, 2026
traded Jun 15, 2026
+2dSEC FORM 4

Evidence

21
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,954 sh
Jun 12, 2026Jun 16, 2026
traded Jun 12, 2026
+4dSEC FORM 4

Evidence

9
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,954 sh
Jun 12, 2026Jun 16, 2026
traded Jun 12, 2026
+4dSEC FORM 4

Evidence

19
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC FORM 4

Evidence

31
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC FORM 4

Evidence